SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-19-010818
Filing Date
2019-11-12
Accepted
2019-11-12 16:31:46
Documents
65
Period of Report
2019-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q nbrv-20190930x10q.htm 10-Q 2238340
2 EX-10.1 nbrv-20190930ex101e439b0.htm EX-10.1 112511
3 EX-31.1 nbrv-20190930ex31157b581.htm EX-31.1 12814
4 EX-31.2 nbrv-20190930ex3120cda40.htm EX-31.2 12704
5 EX-32.1 nbrv-20190930ex321d8eb5d.htm EX-32.1 7449
6 EX-32.2 nbrv-20190930ex3224e0131.htm EX-32.2 7236
  Complete submission text file 0001558370-19-010818.txt   7386246

Data Files

Seq Description Document Type Size
7 EX-101.INS nbrv-20190930.xml EX-101.INS 1322337
8 EX-101.SCH nbrv-20190930.xsd EX-101.SCH 54486
9 EX-101.CAL nbrv-20190930_cal.xml EX-101.CAL 51394
10 EX-101.DEF nbrv-20190930_def.xml EX-101.DEF 263236
11 EX-101.LAB nbrv-20190930_lab.xml EX-101.LAB 498098
12 EX-101.PRE nbrv-20190930_pre.xml EX-101.PRE 408455
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37558 | Film No.: 191210019
SIC: 2834 Pharmaceutical Preparations